ATE542529T1 - Verwendung von l-carnitin zur behandlung von herz-kreislauf-erkrankungen - Google Patents

Verwendung von l-carnitin zur behandlung von herz-kreislauf-erkrankungen

Info

Publication number
ATE542529T1
ATE542529T1 AT05755616T AT05755616T ATE542529T1 AT E542529 T1 ATE542529 T1 AT E542529T1 AT 05755616 T AT05755616 T AT 05755616T AT 05755616 T AT05755616 T AT 05755616T AT E542529 T1 ATE542529 T1 AT E542529T1
Authority
AT
Austria
Prior art keywords
carnitine
infarction
grams
days
reducing
Prior art date
Application number
AT05755616T
Other languages
English (en)
Inventor
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE542529T1 publication Critical patent/ATE542529T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05755616T 2004-07-13 2005-06-21 Verwendung von l-carnitin zur behandlung von herz-kreislauf-erkrankungen ATE542529T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000346A ITRM20040346A1 (it) 2004-07-13 2004-07-13 Uso della l-carnitina per il trattamento di patologie cardiovascolari.
PCT/EP2005/006657 WO2006005415A2 (en) 2004-07-13 2005-06-21 Use of l-carnitine and glucose for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
ATE542529T1 true ATE542529T1 (de) 2012-02-15

Family

ID=34971575

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05755616T ATE542529T1 (de) 2004-07-13 2005-06-21 Verwendung von l-carnitin zur behandlung von herz-kreislauf-erkrankungen

Country Status (22)

Country Link
US (2) US7879908B2 (de)
EP (1) EP1773314B1 (de)
JP (1) JP5230195B2 (de)
KR (1) KR101296479B1 (de)
CN (2) CN101087602B (de)
AT (1) ATE542529T1 (de)
AU (1) AU2005262050B2 (de)
BR (1) BRPI0513303A8 (de)
CA (1) CA2569888C (de)
CY (1) CY1112686T1 (de)
DK (1) DK1773314T3 (de)
ES (1) ES2380913T3 (de)
HK (2) HK1113542A1 (de)
HR (1) HRP20120178T1 (de)
IT (1) ITRM20040346A1 (de)
ME (1) ME01345B (de)
MX (1) MXPA06014665A (de)
PL (1) PL1773314T3 (de)
PT (1) PT1773314E (de)
RS (1) RS52253B (de)
SI (1) SI1773314T1 (de)
WO (1) WO2006005415A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) * 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
JPS6415220A (en) 1987-07-06 1989-01-19 Mitsubishi Electric Corp Tension control device for utilizing maximum torque and maximum electric current of winding motor
JPH06102624B2 (ja) * 1990-08-10 1994-12-14 アース製薬株式会社 非心臓由来の不整脈防止薬
IT1261695B (it) * 1993-06-02 1996-05-29 Sigma Tau Ind Farmaceuti Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono.
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
CA2352485A1 (en) * 1998-11-26 2000-06-02 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia
HUP0203441A3 (en) * 1999-10-11 2004-01-28 Sigma Tau Ind Farmaceuti Use of l-carnitine and its alkanoyl derivatives as osmotic agents and solutions for medical use
CA2480557C (en) * 2002-04-01 2013-02-19 Gary David Lopaschuk Cycloalkylcarboxyl derivatives that stimulate glucose utilization and methods of use
ITRM20030178A1 (it) * 2003-04-17 2004-10-18 Sigma Tau Ind Farmaceuti Uso della l-carnitina per il trattamento di patologie cardiovascolari.

Also Published As

Publication number Publication date
CY1112686T1 (el) 2016-02-10
US20070207970A1 (en) 2007-09-06
JP5230195B2 (ja) 2013-07-10
CN102349923A (zh) 2012-02-15
AU2005262050B2 (en) 2011-02-24
HK1166003A1 (zh) 2012-10-19
WO2006005415A2 (en) 2006-01-19
US7879908B2 (en) 2011-02-01
BRPI0513303A (pt) 2008-05-06
CN101087602B (zh) 2011-09-14
US20110086917A1 (en) 2011-04-14
HRP20120178T1 (hr) 2012-05-31
CA2569888A1 (en) 2006-01-19
SI1773314T1 (sl) 2012-04-30
EP1773314B1 (de) 2012-01-25
JP2008517872A (ja) 2008-05-29
PT1773314E (pt) 2012-03-29
ME01345B (me) 2012-10-31
CN101087602A (zh) 2007-12-12
PL1773314T3 (pl) 2012-06-29
HK1113542A1 (en) 2008-10-10
CA2569888C (en) 2013-08-13
DK1773314T3 (da) 2012-05-07
RS52253B (en) 2012-10-31
EP1773314A2 (de) 2007-04-18
MXPA06014665A (es) 2007-03-12
ES2380913T3 (es) 2012-05-21
AU2005262050A1 (en) 2006-01-19
US8394854B2 (en) 2013-03-12
BRPI0513303A8 (pt) 2017-12-26
KR101296479B1 (ko) 2013-08-13
WO2006005415A3 (en) 2006-05-26
CN102349923B (zh) 2016-04-27
KR20070039541A (ko) 2007-04-12
ITRM20040346A1 (it) 2004-10-13

Similar Documents

Publication Publication Date Title
RU2015103107A (ru) Комбинированная композиция
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
JP5030553B2 (ja) ドライマウスおよび／または唾液分泌障害を処置するための医薬
RU2009101026A (ru) Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии
ATE542529T1 (de) Verwendung von l-carnitin zur behandlung von herz-kreislauf-erkrankungen
Kayrak et al. Lithium intoxication causing ST segment elevation and wandering atrial rhythms in an elderly patient
JP4381685B2 (ja) ２型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルｌ−カルニチンの使用
MXPA05007612A (es) Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares.
Martorell-Calatayud et al. Multiple painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea
KR20210097487A (ko) 후코이단을 포함하는 수면장애 예방, 개선 또는 치료용 조성물
CN111068058A (zh) PGC-1α激活剂在制备治疗脓毒症药物中的应用
RU2006110550A (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
JP2006045200A (ja) 間質性膀胱炎の治療薬
JP2009539941A (ja) Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
ROY et al. Milestones In Diabetes Research
Ayache et al. Methylphenidate in a patient with depression and respiratory insufficiency
Gareri et al. Valproate-induced delirium in a demented patient
PE20240241A1 (es) Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo
Rachmilewitz et al. Electrocardiographic changes and the effect of niacin therapy in pellagra
McDaniel Antidepressant activity of linezolid
Goldberg, B., Levin, NW, Rubinstein, A. & Cohen Alpha-methyldopa in hypertension
JP2008517872A5 (de)
JP5707137B2 (ja) レバミピドの骨粗鬆症治療用途
CN109602811A (zh) 一种治疗冠心病的药物
Sahin Kavakli et al. A rare cause of severe bradycardia and hypotension: mad honey poisining